biostudies-literatureLu YNIH HHS530https://www.ebi.ac.uk/biostudies/studies/S-EPMC6345854biostudies-literatureUnknown9(1)Cell culture and protein target-based compound screening strategies, though broadly utilized in selecting candidate compounds, often fail to eliminate candidate compounds with non-target effects and/or safety concerns until late in the drug developmental process. Phenotype screening using intact research animals is attractive because it can help identify small molecule candidate compounds that have a high probability of proceeding to clinical use. Most FDA approved, first-in-class small molecules were identified from phenotypic screening. However, phenotypic screening using rodent models is labor intensive, low-throughput, and very expensive. As a novel alternative for small molecule screening, we have been developing gene expression disease profiles, termed the Transcriptional Disease SigScientific reportsApplication of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.PMC6345854R24 OD011198R24 OD011120R24 OD018555Regneri JSchartl MSavage MLu YBoswell MKlotz BMendoza CWalter RBBoswell WKneitz SWarren WCPostlethwait JfalseApplication of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.Cell culture and protein target-based compound screening strategies, though broadly utilized in selecting candidate compounds, often fail to eliminate candidate compounds with non-target effects and/or safety concerns until late in the drug developmental process. Phenotype screening using intact research animals is attractive because it can help identify small molecule candidate compounds that have a high probability of proceeding to clinical use. Most FDA approved, first-in-class small molecules were identified from phenotypic screening. However, phenotypic screening using rodent models is labor intensive, low-throughput, and very expensive. As a novel alternative for small molecule screening, we have been developing gene expression disease profiles, termed the Transcriptional Disease Sig2019-01-01T00:00:00Z2019 Jan2025-04-26T08:55:56.378Z2019-03-26T22:41:53ZS-EPMC63458543067961910.1038/s41598-018-36656-x